{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:31:24Z","timestamp":1762241484906,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"DOI":"10.7759\/cureus.96049","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:26:39Z","timestamp":1762241199000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Oral Mesalamine on Clinical Remission and Mucosal Response in Mild to Moderate Ulcerative Colitis: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Laiba","family":"Nabeel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Khurshid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammarah","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Abbas Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hifza","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoukat","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Rizwan","family":"Umer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan Ahmad","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Iftikhar","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-020-00246-4","article-title":"Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies","volume":"17","author":"Kaur A","year":"2020","unstructured":"Kaur A, Goggolidou P. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. J Inflamm (Lond). 2020, 17:15. 10.1186\/s12950-020-00246-4","journal-title":"J Inflamm (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal JP","year":"2021","unstructured":"Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021, 21:135-9. 10.7861\/clinmed.2021-0080","journal-title":"Clin Med (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001685","article-title":"Urgency and its association with quality of life and clinical outcomes in patients with ulcerative colitis","volume":"117","author":"Sninsky JA","year":"2022","unstructured":"Sninsky JA, Barnes EL, Zhang X, Long MD. Urgency and its association with quality of life and clinical outcomes in patients with ulcerative colitis. Am J Gastroenterol. 2022, 117:769-76. 10.14309\/ajg.0000000000001685","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du L","year":"2020","unstructured":"Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020, 49:643-54. 10.1016\/j.gtc.2020.07.005","journal-title":"Gastroenterol Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Le Berre C","year":"2020","unstructured":"Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther. 2020, 20:363-78. 10.1080\/14712598.2019.1666101","journal-title":"Expert Opin Biol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01560-6","article-title":"Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study","volume":"32","author":"Bahaa MM","year":"2024","unstructured":"Bahaa MM, Hegazy SK, Maher MM, Bahgat MM, El-Haggar SM. Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study. Inflammopharmacology. 2024, 32:3247-58. 10.1007\/s10787-024-01560-6","journal-title":"Inflammopharmacology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020226","article-title":"pH-dependent drug delivery systems for ulcerative colitis treatment","volume":"17","author":"Gvozdeva Y","year":"2025","unstructured":"Gvozdeva Y, Staynova R. pH-dependent drug delivery systems for ulcerative colitis treatment. Pharmaceutics. 2025, 17:226. 10.3390\/pharmaceutics17020226","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0676-y","article-title":"Mucosal healing in ulcerative colitis: a comprehensive review","volume":"77","author":"Boal Carvalho P","year":"2017","unstructured":"Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: a comprehensive review. Drugs. 2017, 77:159-73. 10.1007\/s40265-016-0676-y","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Shah SC","year":"2016","unstructured":"Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016, 14:1245-1255.e8. 10.1016\/j.cgh.2016.01.015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon H","year":"2020","unstructured":"Yoon H, Jangi S, Dulai PS, et al.. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology. 2020, 159:1262-1275.e7. 10.1053\/j.gastro.2020.06.043","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092905","article-title":"Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis","volume":"9","author":"Solitano V","year":"2020","unstructured":"Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. J Clin Med. 2020, 9:2905. 10.3390\/jcm9092905","journal-title":"J Clin Med"},{"key":"ref12","unstructured":"Ulcerative colitis. clinical trial endpoints. Food and Drug Administration. (2016). Accessed: n.d: https:\/\/www.fda.gov\/media\/99526\/download."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221136331","article-title":"Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program","volume":"15","author":"Sandborn WJ","year":"2022","unstructured":"Sandborn WJ, Sands BE, Vermeire S, et al.. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap Adv Gastroenterol. 2022, 15:17562848221136331. 10.1177\/17562848221136331","journal-title":"Therap Adv Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab007","article-title":"Full, partial, and modified permutations of the Mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients","volume":"3","author":"Naegeli AN","year":"2021","unstructured":"Naegeli AN, Hunter T, Dong Y, et al.. Full, partial, and modified permutations of the Mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. Crohns Colitis 360. 2021, 3:otab007. 10.1093\/crocol\/otab007","journal-title":"Crohns Colitis 360"},{"key":"ref15","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb CA","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al.. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019, 68:1-106.","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987, 317:1625-9. 10.1056\/NEJM198712243172603","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.069","article-title":"Delayed-release oral mesalamine 4.8 g\/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis","volume":"137","author":"Sandborn WJ","year":"2009","unstructured":"Sandborn WJ, Regula J, Feagan BG, et al.. Delayed-release oral mesalamine 4.8 g\/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009, 137:1934-43.e1-3. 10.1053\/j.gastro.2009.08.069","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/01.ibd.0000225345.29603.7d","article-title":"Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis","volume":"12","author":"Picco MF","year":"2006","unstructured":"Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. Inflamm Bowel Dis. 2006, 12:537-42. 10.1097\/01.ibd.0000225345.29603.7d","journal-title":"Inflamm Bowel Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.2","article-title":"Mesalamine in the treatment and maintenance of remission of ulcerative colitis","volume":"5","author":"Ham M","year":"2012","unstructured":"Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012, 5:113-23. 10.1586\/ecp.12.2","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan BG","year":"2012","unstructured":"Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012, 18:1785-94. 10.1002\/ibd.23024","journal-title":"Inflamm Bowel Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/2050640617703842","article-title":"Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial","volume":"6","author":"Dignass A","year":"2018","unstructured":"Dignass A, Schnabel R, Romatowski J, et al.. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2018, 6:138-47. 10.1177\/2050640617703842","journal-title":"United European Gastroenterol J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv180","article-title":"Mucosal healing in ulcerative colitis-when zero is better","volume":"10","author":"Boal Carvalho P","year":"2016","unstructured":"Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal healing in ulcerative colitis-when zero is better. J Crohns Colitis. 2016, 10:20-5. 10.1093\/ecco-jcc\/jjv180","journal-title":"J Crohns Colitis"},{"key":"ref23","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial","volume":"88","author":"Hanauer S","year":"1993","unstructured":"Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993, 88:1188-97.","journal-title":"Am J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6923609","article-title":"The efficacy and safety of mesalamine and probiotics in mild\u2010to\u2010moderate ulcerative colitis: a systematic review and meta\u2010analysis","volume":"2020","author":"Tian C","year":"2020","unstructured":"Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The efficacy and safety of mesalamine and probiotics in mild\u2010to\u2010moderate ulcerative colitis: a systematic review and meta\u2010analysis. Evid Based Complement Alternat Med. 2020, 2020:6923609. 10.1155\/2020\/6923609","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399203-impact-of-oral-mesalamine-on-clinical-remission-and-mucosal-response-in-mild-to-moderate-ulcerative-colitis-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:26:42Z","timestamp":1762241202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399203-impact-of-oral-mesalamine-on-clinical-remission-and-mucosal-response-in-mild-to-moderate-ulcerative-colitis-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.96049","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}